Innovative lead discovery strategies for tropical diseases

Nature Reviews Drug Discovery

Volumn 5, Issue 11, 2006, Pages 941-955

  Nwaka, Solomon ^a   Hudson, Alan ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMPHOTERICIN B LIPID COMPLEX; ANTIMALARIAL AGENT; ANTIMONY DERIVATIVE; ANTIPROTOZOAL AGENT; ARTEETHER; ARTEMETHER; ARTEMISIN DERIVATIVE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; BENZIMIDAZOLE; CHLOROQUINE; DIETHYLCARBAMAZINE; EFLORNITHINE; FANSIDAR; HALOFANTRINE; IVERMECTIN; K 777; MEFLOQUINE; MELARSOPROL; MILTEFOSINE; MOXIDECTIN; NIFURTIMOX; OXAMNIQUINE; PENTAMIDINE; PRAZIQUANTEL; PRIMAQUINE; QUININE; SURAMIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AFRICAN TRYPANOSOMIASIS; CHAGAS DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; DRUG RESEARCH; HUMAN; INDUSTRIALIZATION; LEISHMANIASIS; MALARIA; NONHUMAN; ONCHOCERCIASIS; ORGANIZATION AND MANAGEMENT; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; SCHISTOSOMIASIS; SCHOOL; SPECIES ENDEMICITY; STRATEGIC PLANNING; TROPICAL DISEASE; TUBERCULOSIS;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACOLOGY; TROPICAL MEDICINE;

EID: 33750531864     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2144     Document Type: Review

References (70)

1. Trouiller, P. et al. Drug development for neglected diseases: A deficient market and a public-health policy failure. Lancet 359, 2188-2195 (2002).
2. Nwaka, S. & Ridley, R. G. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nature Rev. Drug Discov. 2, 919-928 (2003).
3. World Health Organization. World Health Report (2004).
4. Nwaka, S. Drug discovery and beyond: The role of public-private partnerships in improving access to new malaria medicines. Trans. Royal Soc. Trop. Med. Hygiene 99, S20-S29 (2005).
5. Pink, R. et al. Opportunities and challenges in antiparasitic drug discovery. Nature Rev. Drug Discov. 4, 727-740 (2005).
6. Bleicher, K. H. et al. Hit and lead generation: Beyond high-throughput screening. Nature Rev. Drug Discov. 2, 369-378 (2003).
7. Vennerstrom, J. L. et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430, 900-904 (2004).
8. TDR News Number 73 (2004).
9. Moran, M. et al. The New Landscape for Neglected Diseases Drug Development (Wellcome Trust, London, 2005).
10. Nwaka, S. & Widdus, R. in Combating Diseases Associated with Poverty: Financing Strategies for Product Development and the Potential Role of Public-Private Partnerships (eds Widdus, R. & White, K.) 164-168 (Initiative on Public-Private Partnerships for Health, Geneva. (2004).
11. Report of the Commission on Intellectual Property Rights, Innovation and Public Health. Public Health, Innovation and Intellectual Property Rights (CIPIH) (World Health Organization, 2006).
12. International Federation of Pharmaceutical Manufacturers Association. Research and Development for Neglected Diseases: Lessons Learned and Remaining Challenges (IFPMA, 2005).
13. Malaria research and development: An assessment of global investment. Malaria R&D Alliance Report (2005).
14. Hotez, P. et al. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med. 3 (2006).
15. Report of the Commission for Africa. Our Common Interest [online], (2005).
16. Fairlamb, A. H. Target discovery and validation with special reference to trypanothione. In Drugs against parasitic diseases: R&D methodologies and issues (eds Fairlamb, A. H., Ridley, R. G. & Vial, H. J.) 107-118 (WHO/TDR, Geneva 2003).
17. Behm, C. A. et al. RNAi-based discovery and validation of new drug targets in filarial nematodes. Trends Parasitol. 21, 97-100 (2005).
18. Rosenthal, P. J. Antimalarial drug discovery: Old and new approaches. J. Exp. Biol. 206, 3735-3744 (2003).
19. Witty, M. Current strategies in the search for novel antiparasitic agents. Int. J. Parasitol. 29, 95-103 (1999).
20. Remme, J. H. F. et al. Strategic emphasis for tropical diseases research: A TDR perspective. Trends Parasitol. 18, 421-425 (2002).
21. Ridley, R. G. Research on infectious diseases requires better coordination. Nature Med. 10, S137-140 (2004).
22. Horton, J. Drug development for tropical diseases - present situation, future perspectives. Trends Parasitol. 19, P06 (2003).
23. Omura, S. and Crump, A. The life and times of ivermectin - a success story. Nature Rev. Microbiol. 2, 984-989 (2004).
24. Cotreau, M. M. et al. The antiparasitic moxidectin: Safety, tolerability, and pharmacokinetics in humans. J. Clin. Pharmacol. 43, 1108-1115 (2003).
25. Fidock, D. A. et al. Antimalarial drug discovery: Efficacy models for compound screening. Nature Rev. Drug Discov. 3, 509-520 (2004).
26. Gelb, M. H. et al. Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol. Biochem. Parasitol. 126, 155-163 (2003).
27. Andrews, K. T. et al. Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents. Intl. J. Parasitol. 30, 761-768 (2000).
28. Gardner, M. J. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 419, 498-511 (2002).
29. El-Sayed, N. M. et al. Comparative genomics of trypanosomatid parasitic protozoo. Science 309, 404-409 (2005).
30. Mitreva, M. et al. Comparative genomics of nematodes. Trends Genet. 21, 573-281 (2005).
31. Joachimiak, M. P. et al. The impact of whole genome sequence data on drug discovery - a malaria case study. Mol. Med. 7, 698-710 (2001).
32. Jones, A. K. et al. Chemistry-to-gene screens in Caenorhabditis elegans. Nature Rev. Drug Discov. 4, 321-330 (2005).
33. Bajorath, J. Integration of virtual and high-throughput screening. Nature Rev. Drug Discov. 1, 882-893 (2002).
34. Mackey, Z. B. et al. Discovery of Trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chem. Biol. Drug Des. 67, 355-363 (2006).
35. Chong, C. R. et al. A clinical drug library screen identifies astemizole as an antimalarial agent. Nature Chem. Biol. 2, 415-416 (2006).
36. Lipinski, C. & Hopkins, A. Navigating chemical space for biology and medicine. Nature 432, 855-861 (2004).
37. Paolini G. V. et al. Global mapping of pharmacological space. Nature Biotechnol. 24, 805-815 (2006).
38. Clark, D. E. and Pickett, S. D. Computational methods for the prediction of 'drug-likeness'. Drug Discov Today 5, 49-58 (2000).
39. Yuvaniyama, J. et al. Insights into antifolate resistance from malarial DHFR-TS structures. Nature Struct. Biol. 10, 357-367 (2003).
40. Kuo, M. R. et al. Targeting tuberculosis and malaria through inhibition of enoyl reductase: Compound activity and structural data. J. Biol. Chem. 278, 20851-20859 (2003).
41. Blundell, T. L. et al. High-throughput crystallography for lead discovery in drug design. Nature Rev. Drug Discov. 1, 45-54 (2002).
42. Anderson, A. C. The process of structure-based drug design. Chem. Biol. 10, 787-797 (2003).
43. Cos, P. et al. Anti-infective potential of natural products: How to develop a stronger in vitro 'proof-of-concept'. J. Ethnopharmacol. 106, 290-302 (2006).
44. Bush, K., Macielag, M. & Weidner-Wells, M. Taking inventory: antibacterial agents currently at or beyond phase I. Curr. Opin. Microbiol. 7, 466-476 (2004).
45. Overbye, K. M. & Barrett, J. F. Antibiotics: Where did we go wrong? Drug Discov. Today 10, 45-52 (2005).
46. Gribbon, P. & Sewing, A. High throughput drug discovery: What can we expect from HTS? Drug Discov. Today 10, 17-22 (2005).
47. Barr, S. C. et al. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob. Agents Chemother. 49, 5160-5160 (2005).
48. Cohen, J. Public health. Gates Foundation picks winners in Grand Challenges in Global Health. Science 309, 33-35 (2005).
49. Sturk, L. M. et al. Distribution and quantitation of the anti-trypanosomal diamidine 2, 5-bis(4-amidinophenyl) furan (DB75) and its N-methoxy prodrug DB289 in murine brain tissue. Acta Trop. 91, 131-43 (2004).
50. McKerrow, J. H. Designing drugs for parasitic diseases of the developing world. PLoS Med. 2 (2005).
51. Dalrymple, M. et al. Academia-industry partnerships in drug discovery. Expert Opin. Drug Discov. 1, 1-5 (2006).
52. Brown, E. Screening in academe: A perspective on implementation of university-based small molecule screening. J. Biomol. Screen. 8, 377-379 (2003).
53. Stein, R. High-throughput in academia: The Harvard experience. J. Biomol. Screen. 8, 615-619 (2003).
54. Morel, C. et al. Health innovation networks to help developing countries address neglected diseases. Science 309, 401-404 (2005).
55. Hasan, S. et al. Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis. PLOS Comp. Biol. 2, e61 (2006).
56. Moran M. A breakthrough in R&D for Neglected diseases: New ways to get the drugs we need. PLoS Med. 2 (2005).
57. Hopkins, A. L. and Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727-730 (2002).
58. Buckner, F. S. et al. Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. Curr. Opin. Investig. Drugs. 6, 791-797 (2005).
59. Perrin, D., Scheer, A. & Wells T. Collaborating to find new approaches to tropical diseases. Eur. Pharma. Rev. 3, 52-55 (2006).
60. G8 Gleneagles Communique on Africa [online], (2005).
61. Juma, C. & Yee-Cheong, L. UN Millenium Project- task force on science, technology and innovation [online], (2005).
62. DiMasi, J., Hansen, R., and Grabowski, H. The price of innovation: New estimates of drug development costs. J. Health Econ. 22, 325-330 (2003).
63. MMV business plan (2003).
64. Gutteridge, W. E. TDR collaboration with pharmaceutical industry. Trans. Royal Soc. Trop. Med. Hyg. 24 May 2006 [epub ahead of print].
65. Baldwin, J. et al. High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J. Biol. Chem. 280, 21847-21853 (2005).
66. Gelb, M. H. & Hol, W. G. Parasitology. Drugs to combat tropical protozoan parasites. Science, 297, 343-344 (2002).
67. Bahl, A. et al. PlasmoDB: The Plasmodium genome resource. A database integrating experimental and computational data. Nucleic Acids Res. 31, 212-215 (2003).
68. Maurer, S. M., Rai A., and Sali A. Finding cures for tropical diseases: is open source an answer? PLoS Med. 3, e56 (2004).
69. Spencer, A. P. The challenges of managing a compound collection. Eur. Pharma Rev. 51-57 (2004).
70. Yates, I. Compound management comes of age. Drug Discov. World 4, 35-42 (2003).